

## Format for ANSWERING REVIEWERS



November 01, 2012

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 5435-Review.doc).

**Title:** Treatment of temozolomide in brain metastases: A review of 21 clinical trials

**Author:** Wei Zhu, Li Zhou, Jiaqi Qian, Tianzhu Qiu, Yongqian Shu, Ping Liu

**Name of Journal:** *World Journal of Clinical Oncology*

**ESPS Manuscript NO:** 5435

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

**(1) Reviewer 1:**

This is an interesting article demonstrated a descriptive results concerning the temozolomide on various clinical trials for patients with brain metastases derived from various cancers. Although the aim of this study is to provide more persuade evidence to use temozolomide for brain metastasis. Results could lack scientific evidence due to the heterogeneity of patients, regimens clinical setting. Failure to conduct a meta-analysis is also a weakness of this study. The authors are suggested to limit their focus to a certain cancer (NSCLC or melanoma) to compare the different protocol in order to provide more scientific insights on this drug.

**Response:**

Exactly, we originally intended to conduct a meta-analysis on temozolomide for brain metastasis, however, we found that the clinical research so far on this topic was not quite enough to satisfy our purpose, so we finally decided to write a systematic review. The reviewer suggested to limit the focus to a certain cancer, it was a good suggestion, however, the information in this manuscript had provided various cancer including NSCLC or melanoma, so we think this review could give a more comprehensive introduction on this topic. Thanks for the attention on our manuscript.

**(2) Reviewer 2:**

This is a reasonable paper summarizing the known experience with temazolamide for the treatment of brain metastases from solid tumors. It apparently began as a meta-analysis, but this had to be abandoned. One small correction: I would list response rates as percentages, and not as proportions--it is confusing.


**Response:** It was a good suggestion to list response rates as percentages, we showed the treatment effect more specifically in order to provide more details on this topic. Anyway, it was a good advice for consideration in our future manuscript writing. Thanks!

3 References and typesetting were corrected

Yes, but there was several papers with no doi number, so we did not provide it in the references.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Louping', written in a cursive style.

MD, PHD, Chief Physician of the Dep. Oncology of First Affiliated Hospital of Nanjing Medical University, Professor of Oncology of Nanjing Medical University. The address: Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China.

E-mail: [belliwether@163.com](mailto:belliwether@163.com)

Telephone: +86-2583718836-6080

Fax: +86-2583780826